治疗便秘型肠易激综合征新药替那帕诺(4)
[9] Zielińska M， Wasilewski A， Fichna J. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome[J]. Expert Opin Investig Drugs， 2015， 24(8)： 1093-1099.
[10] Block GA， Rosenbaum DP， Yan A， et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis： a randomized phase 3 trial[J]. J Am Soc Nephrol， 2019， 30(4)： 641-652.
[11] Block GA， Rosenbaum DP， Yan A， et al. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia[J]. Nephrol Dial Transplant， 2019， 34(2)： 339-346.
[12] Johansson S， Rosenbaum DP， Ahlqvist M， et al. Effects of tenapanor on cytochrome P450-mediated drug-drug Interactions[J]. Clin Pharmacol Drug Dev， 2017， 6(5)： 466-475.
[13] Johansson SA， Knutsson M， Leonsson-Zachrisson M， et al. Effect of food intake on the pharmacodynamics of tenapanor： a phase 1 study[J]. Clin Pharmacol Drug Dev， 2017， 6(5)： 457-465., 百拇医药(张德高 柳涛 杨忠英 姜云达)
[10] Block GA， Rosenbaum DP， Yan A， et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis： a randomized phase 3 trial[J]. J Am Soc Nephrol， 2019， 30(4)： 641-652.
[11] Block GA， Rosenbaum DP， Yan A， et al. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia[J]. Nephrol Dial Transplant， 2019， 34(2)： 339-346.
[12] Johansson S， Rosenbaum DP， Ahlqvist M， et al. Effects of tenapanor on cytochrome P450-mediated drug-drug Interactions[J]. Clin Pharmacol Drug Dev， 2017， 6(5)： 466-475.
[13] Johansson SA， Knutsson M， Leonsson-Zachrisson M， et al. Effect of food intake on the pharmacodynamics of tenapanor： a phase 1 study[J]. Clin Pharmacol Drug Dev， 2017， 6(5)： 457-465., 百拇医药(张德高 柳涛 杨忠英 姜云达)